Summary
This 120-day randomised controlled trial in 60 MASLD patients evaluated the therapeutic potential of conjugated linoleic acid-enriched fermented dairy using multi-omics and causal inference methods. The intervention significantly reduced liver function markers and inflammatory biomarkers whilst promoting beneficial shifts in gut microbiota composition and energy metabolism pathways. Causal mediation analysis identified specific bacterial taxa and metabolites as key mediators linking dietary CLA to clinical improvements, highlighting the value of mechanistic multi-omics approaches in understanding diet–host–microbiota interactions in metabolic disease.
Regional applicability
The trial methodology and findings are potentially applicable to United Kingdom populations with MASLD, as the condition's epidemiology and underlying pathophysiology are comparable. However, the study geography is not explicitly stated in the abstract; transferability to UK clinical practice would depend on confirmation of the study location, replication in UK cohorts, and alignment with current National Health Service dietary guidance for metabolic liver disease management.
Key measures
Serum ALT, total cholesterol, creatinine, hs-CRP; gut microbiota composition (16S rRNA); serum metabolites (untargeted LC–MS); causal mediation analysis
Outcomes reported
The study measured changes in liver function markers (ALT, total cholesterol, creatinine, hs-CRP), gut microbiota composition via 16S rRNA sequencing, and serum metabolites via LC–MS metabolomics in MASLD patients after 120 days of CLA-enriched fermented dairy consumption. Causal mediation analyses identified mechanistic links between the intervention, microbiota shifts, metabolic changes, and clinical improvements.
Topic tags
Dig deeper with Pulse AI.
Ask about this record, its theme or its relevance to UK farming and policy. Pulse AI uses selected catalogue evidence and cites the sources it draws on.